Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368849 · ClinicalTrials.gov registry record · Phase 2
Atomoxetine and Huntington's Disease
A Phase 2 study of Huntington Disease and Chorea, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00368849: Completed Phase 2 study of Huntington Disease and Chorea, sponsored by University of Iowa.
NCT00368849 is a Phase 2 study of Huntington Disease and Chorea that has completed, run by University of Iowa. The registered enrollment target is 20 participants, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00368849, a Phase 2 study of Huntington Disease and Chorea, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements in subjects with early Huntington Disease (HD) and attention deficit disorder (ADD).
Primary Outcome
The Conners' Adult Attention Rating Scale (CAARS) is one of the most frequently used self-rating measures for adult Attention Deficit Hyperactivity Disorder (ADHD) and was given as a self-report measure of attention. It has 66 items with each item ranging from 0 to 3 points. Higher total scores represent greater impairment. The outcome reported was change in score from baseline for each treatment arm.
Conditions Studied
Interventions
- DRUG Matching Placebo
- DRUG atomoxetine
Study Locations (1)
Iowa
- The University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT00368849 record still lists
NCT00368849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT00368849 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT00368849 about?
NCT00368849 is a clinical study titled "Atomoxetine and Huntington's Disease". The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements in subjects with early Huntington Disease (HD) and attention deficit d...
What is the current status of trial NCT00368849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-11. Estimated completion is 2008-02.
What conditions does trial NCT00368849 study?
This clinical trial studies the following conditions: Huntington Disease, Chorea.
What interventions are being tested in trial NCT00368849?
The interventions under investigation include: Matching Placebo (DRUG), atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00368849?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00368849 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00368849's enrollment target sits among peer trials
20 29th of 35 higher than 5 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
ACTIVE NOT RECRUITING · Phase 2
-
Creatine Safety and Tolerability in Premanifest HD: PRECREST
COMPLETED · Phase 2
-
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
COMPLETED · Phase 2
-
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
COMPLETED · Phase 2
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia